International COVID-19 Blood Cancer Coalition (ICBCC) – Patient Impact Statement and Recommendations

Protecting immunocompromised blood cancer patients during the COVID-19 pandemic

The coalition has prepared a Joint Patient Impact Statement for use in different countries to aid when advocating for the provision of anti-COVID-19 treatment and care for immunocompromised or immunosuppressed (IC/IS) blood cancer patients.

The Statement has to date been endorsed by networks and national organisations of the global patient advocacy community as well as renowned medical societies and representatives from the global clinical community .

There is a total of 71 endorsers to date including CLL Advocates NZ, Dr Gillian Corbett.